Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy
Hypertensive patients unable to reach blood pressure (BP) targets with antihypertensive monotherapy may be switched to a combination of two medications with complementary modes of action for improved treatment response. This post hoc analysis pools data from 2812 patients, 1891 of whom were not at g...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2013/627938 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561516914671616 |
|---|---|
| author | Steen Neldam Dingliang Zhu Helmut Schumacher |
| author_facet | Steen Neldam Dingliang Zhu Helmut Schumacher |
| author_sort | Steen Neldam |
| collection | DOAJ |
| description | Hypertensive patients unable to reach blood pressure (BP) targets with antihypertensive monotherapy may be switched to a combination of two medications with complementary modes of action for improved treatment response. This post hoc analysis pools data from 2812 patients, 1891 of whom were not at goal (diastolic BP [DBP] <90 mm Hg) with amlodipine 5 mg (A5) monotherapy who subsequently switched to telmisartan 40 or 80 mg (T80)/A5 single-pill combination (SPC) or amlodipine 10 mg (A10) monotherapy, and considers an additional 921 patients, 616 of whom were not at goal with A10 monotherapy who switched to telmisartan/amlodipine SPC. Patients switched to telmisartan/amlodipine SPC achieved significantly greater BP reductions compared with continued monotherapy (P<0.0001) with reductions of −15.2/−10.9 mm Hg seen with T80/A5 after 8 weeks in patients switched from A5. BP goal (<140/90 mm Hg), systolic BP goal (<140 mm Hg), and DBP goal (<90 mm Hg) were reached by significantly more patients with telmisartan/amlodipine than with monotherapy (P<0.0001 for all comparisons; 56.1%, 69.7%, and 66.9%, resp., in patients who switched from A5 to T80/A5). Early use of such combination therapy should be considered to quickly reach BP targets, particularly in patients with added risk. |
| format | Article |
| id | doaj-art-a689acb004c54f03b1022f4e4460637f |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-a689acb004c54f03b1022f4e4460637f2025-02-03T01:24:53ZengWileyInternational Journal of Hypertension2090-03842090-03922013-01-01201310.1155/2013/627938627938Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB MonotherapySteen Neldam0Dingliang Zhu1Helmut Schumacher2Rodøvre Centrum 294, 2610 Rodøvre, DenmarkShanghai Ruijin Hospital, Shanghai Institute of Hypertension, 197 Ruijin 2nd Road, Shanghai, ChinaBoehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim am Rhein, GermanyHypertensive patients unable to reach blood pressure (BP) targets with antihypertensive monotherapy may be switched to a combination of two medications with complementary modes of action for improved treatment response. This post hoc analysis pools data from 2812 patients, 1891 of whom were not at goal (diastolic BP [DBP] <90 mm Hg) with amlodipine 5 mg (A5) monotherapy who subsequently switched to telmisartan 40 or 80 mg (T80)/A5 single-pill combination (SPC) or amlodipine 10 mg (A10) monotherapy, and considers an additional 921 patients, 616 of whom were not at goal with A10 monotherapy who switched to telmisartan/amlodipine SPC. Patients switched to telmisartan/amlodipine SPC achieved significantly greater BP reductions compared with continued monotherapy (P<0.0001) with reductions of −15.2/−10.9 mm Hg seen with T80/A5 after 8 weeks in patients switched from A5. BP goal (<140/90 mm Hg), systolic BP goal (<140 mm Hg), and DBP goal (<90 mm Hg) were reached by significantly more patients with telmisartan/amlodipine than with monotherapy (P<0.0001 for all comparisons; 56.1%, 69.7%, and 66.9%, resp., in patients who switched from A5 to T80/A5). Early use of such combination therapy should be considered to quickly reach BP targets, particularly in patients with added risk.http://dx.doi.org/10.1155/2013/627938 |
| spellingShingle | Steen Neldam Dingliang Zhu Helmut Schumacher Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy International Journal of Hypertension |
| title | Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy |
| title_full | Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy |
| title_fullStr | Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy |
| title_full_unstemmed | Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy |
| title_short | Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy |
| title_sort | efficacy of telmisartan plus amlodipine in nonresponders to ccb monotherapy |
| url | http://dx.doi.org/10.1155/2013/627938 |
| work_keys_str_mv | AT steenneldam efficacyoftelmisartanplusamlodipineinnonresponderstoccbmonotherapy AT dingliangzhu efficacyoftelmisartanplusamlodipineinnonresponderstoccbmonotherapy AT helmutschumacher efficacyoftelmisartanplusamlodipineinnonresponderstoccbmonotherapy |